OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Virology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Editorial Board	181
Inhaled aerosol viral-vectored vaccines against tuberculosis	142
Mutational escape from cellular immunity in viral hepatitis: variations on a theme	116
The enigmatic roles of Anelloviridae and Redondoviridae in humans	85
Transmission patterns of hepatitis E virus	85
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?	79
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19	73
Hepatitis-B virus: replication cycle, targets, and antiviral approaches	68
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	65
Future considerations for the mRNA-lipid nanoparticle vaccine platform	64
Colonization of peripheral ganglia by herpes simplex virus type 1 and 2	64
Editorial Board	63
Editorial overview: Viral pathogenesis	62
Virus–host protein interactions as footprints of human cytomegalovirus replication	60
Viral–host interactions during splicing and nuclear export of influenza virus mRNAs	55
Structural basis for neutralization of enterovirus	55
Human placental models for studying viral infections	54
Recent progress in development of monoclonal antibodies against human cytomegalovirus	49
Editorial overview: Mechanisms in the molecular interactions of plants with viruses and viroids	49
Editorial Board	47
The two faces of oligoadenylate synthetase-like: effective antiviral protein and negative regulator of innate immunity	45
Emerging technologies in the study of the virome	44
The journey of herpesvirus capsids and genomes to the host cell nucleus	43
New preventive strategies for respiratory syncytial virus infection in children	42
Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1	40

Paramyxoviruses from bats: changes in receptor specificity and their role in host adaptation	39
Adenovirus – a blueprint for gene delivery	39
Time to ‘Mind the Gap’ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2	38
Shopping for phages? Unpacking design rules for therapeutic phage cocktails	38
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection	36
Epigenetic control of the Epstein-Barr lifecycle	34
The enigma of picobirnaviruses: viruses of animals, fungi, or bacteria?	34
A complex immune communication between eicosanoids and pulmonary macrophages	34
A review of broadly protective monoclonal antibodies to treat Ebola virus disease	33
Engineering therapeutic phages for enhanced antibacterial efficacy	32
Platelets in the pathogenesis of flavivirus disease	31
Mitigation of evolved bacterial resistance to phage therapy	30
Perspective on taxonomic classification of uncultivated viruses	30
Editorial Board	29
Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity	28
Tissue-resident memory T cells in protective immunity to influenza virus	28
Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome: challenges and opportunities	28
Asymmetry in icosahedral viruses	28
Hemagglutinin stability as a key determinant of influenza A virus transmission via air	27
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity	26
When good turns bad: how viruses exploit innate immunity factors	26
Does arbovirus emergence in humans require adaptation to domestic mosquitoes?	26
Retasking of canonical antiviral factors into proviral effectors	26
Mechanisms of HCV resistance to broadly neutralizing antibodies	25
Modeling zoonotic and vector-borne viruses	25
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets	25
MicroRNA-mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications	24
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases	24
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy	24
Oncogenic Animal Herpesviruses	24
Diagnosis and monitoring of virus-associated cancer using cell-free DNA	23
Immune responses to human respiratory coronaviruses infection in mouse models	23
Role of the viral polymerase during adaptation of influenza A viruses to new hosts	23
Deimmunization of flagellin adjuvant for clinical application	22
The impact of high-resolution structural data on stemming the COVID-19 pandemic	22
The virome of vector mosquitoes	22
Bat virome research: the past, the present and the future	21
Editorial overview	21
Advances in human monoclonal antibody therapy for HBV infection	21
Antigenic evolution of SARS coronavirus 2	21
Broadly neutralizing antibodies against COVID-19	20
Fruit bats as natural reservoir of highly pathogenic henipaviruses: balance between antiviral defense and viral tolerance	20
Editorial Board	20
The biology of papillomavirus PDZ associations: what do they offer papillomaviruses?	20
Viral Z-RNA triggers ZBP1-dependent cell death	20
Immunodominance complexity: lessons yet to be learned from dominant T cell responses to SARS-COV-2	19
Editorial Board	19
Editorial overview: Viral immunology before COVID-19	19
Early signaling pathways in virus-infected cells	19
Mapping conformational epitopes by NMR spectroscopy	19

Structure and physiology of giant DNA viruses	19
Editorial overview: Special issue on phage therapy	18
Bacteriophage T4 as a nanovehicle for delivery of genes and therapeutics into human cells	17
Microbiota as a potentially-modifiable factor influencing COVID-19	17
Rotavirus cell entry: not so simple after all	17
The dynamic interactome of microRNAs and the human papillomavirus in head and neck cancers	16
Accumulation of host cell genetic errors following high-risk HPV infection	16
How and why RNA genomes are (partially) ordered in viral capsids	16
Editorial overview: Virus bioinformatics - empowering genomics of pathogens, viromes, and the virosphere across divergence scales	16
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses	15
Bioinformatics of virus taxonomy: foundations and tools for developing sequence-based hierarchical classification	15
Editorial overview: Engineering elimination of chronic viral hepatitis	15
Test it earlier, result it faster, makes us stronger: how rapid viral diagnostics enable therapeutic success	15
The influence of microbiota-derived metabolites on viral infections	15
Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response	15
Structural insights into hepatitis C virus neutralization	15
Editorial overview: Anti-viral strategies: Human antibody immune response and antibody-based therapy against viruses	14
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19	14
Proteases and variants: context matters for SARS-CoV-2 entry assays	14
Editorial overview: Virus structure and expression	14
The intestinal virome: lessons from animal models	14
Editorial overview: Special issue on virus structure and expression in current opinion in virology	14
Advances in the treatment of HTLV-1-associated adult T-cell leukemia lymphoma	14
Editorial Board	13
Editorial Board	13
Fighting viruses with computers, right now	13
Assembly of the virome in newborn human infants	13
Phage therapy for secondary bacterial infections with COVID-19	13
Natural killer cells and unconventional T cells in COVID-19	13
Koala retrovirus and neoplasia: correlation and underlying mechanisms	13
Cryo-EM to visualize the structural organization of viruses	12
European regulatory aspects of phage therapy: magistral phage preparations	12
Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination	12
Virus structure and structure-based antivirals	12
Lying low-chromatin insulation in persistent DNA virus infection	12
Editorial Board	12
Broad neutralizing antibody-based strategies to tackle influenza	12
Editorial Board	11
A comparative review of adenovirus A12 and C5 oncogenes	11
Endocytosis of Bacteriophages	11
Editorial Board	11
Therapeutic approaches to Epstein–Barr virus cancers	11
Animal models of SARS-CoV-2 transmission	11
Integrative structural biology of HIV-1 capsid protein assemblies: combining experiment and computation	11
The female reproductive tract virome: understanding the dynamic role of viruses in gynecological health and disease	11
The more the merrier? Gene duplications in the coevolution of primate lentiviruses with their hosts	11
RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing	11
The role of human lipoproteins for hepatitis C virus persistence	11
Zoonotic disease and virome diversity in bats	11
The long and winding road: human papillomavirus entry and subcellular trafficking	11
Understanding T cell aging to improve anti-viral immunity	10
Viral determinants influencing intra- and intercellular communication in cytomegalovirus infection	10
An overview of the current state of phage therapy for the treatment of biofilm-related infections	10
Ex vivo culture models to study viral infections of the liver	10
Progress and pitfalls of a year of drug repurposing screens against COVID-19	10
Editorial Board	10
Editorial overview: 2022 “Virus–Host Interaction” section of Current Opinion in Virology	10
Editorial Board	10
Co-opted membranes, lipids, and host proteins: what have we learned from tombusviruses?	10
Mechanisms of mucosal immunity at the female reproductive tract involved in defense against HIV infection	10
Pathogenesis of severe acute respiratory syndrome coronavirus-2 in nonhuman primates	10
Know your enemy and know yourself – the case of SARS-CoV-2 host factors	10
Proteomic analysis of antiviral innate immunity	10